A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades.

As a lymphoma survivor, I struggle with the positivity trap — sometimes, I just want my fears validated instead of being ...

The FDA granted Crispr Therapeutics (CRSP) orphan status for its treatment of follicular lymphoma.Don't Miss Our End of Quarter Offers: ...

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

Cancer experiences are highly individualized, even among patients with the same type of cancer, challenging common stereotypes. Follicular lymphoma, a blood cancer, often lacks a single tumor, ...

For those that may not have the opportunity to be part of a clinical trial, Burke proceeds with a step-by-step process. Burke ...

Regarding myeloma, Burke also shares his experience with myeloma BsAbs, saying, “I follow the drug label, administer the drug ...

TAZVERIK ® is a registered trademark of Epizyme Inc., an Ipsen company.